from Breakingviews:

AstraZeneca struggles to advance value defence

November 18, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant’s activist deal too clever by half

November 18, 2014

By Richard Beales and Robert Cyran

The authors are Reuters Breakingviews columnists. The opinions expressed are their own. 

from Breakingviews:

LabCorp deal tests positive for value destruction

November 3, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Amgen boss makes a prime breakup target

October 22, 2014

By Robert Cyran

The author is  a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

AbbVie U-turn shows Shire was mostly about tax

October 15, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

from Breakingviews:

Tax clampdown could deter half-baked pharma M&A

September 23, 2014

By Neil Unmack and Robert Cyran

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

from Breakingviews:

Bayer’s plastic float sows seeds for one more sale

September 18, 2014

By Quentin Webb

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Roche’s $8 bln bet outsmarts ice-bucket challenge

August 25, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

IPO exuberance ensnares Deutsche, Wells Fargo

August 14, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Inversions start to spin out of control

July 30, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.